Study on Prognostic Value of CENPN in Head and Neck Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2023.08.006

Abstract

Abstract: Objective: To investigate the expression and prognostic value of CENPN in head and neck squamous cell carcinoma (HNSCC). Methods: The expression level of CENPN in HNSCC was evaluated in TCGA database. Forty-two cancer tissues resected from HNSCC patients who admitted to the Stomatological Hospital of Guizhou Medical University were chosen to measure CENPN expression by immunohistochemistry. The relationship between CENPN and clinicopathologic feature as well as prognosis was analyzed. Results: The expression level of CENPN was significantly up-regulated in HNSCC (P<0.05). High expression of CENPN was associated with pathological grade. Univariate and multivariate regression analysis demonstrated that age, T stage, and high expression of CENPN were independent prognostic factors in HNSCC. Kaplan-Meier analysis showed that higher expression of CENPN was associated with lower overall survival rate (P<0.05). Conclusion: CENPN was up-regulated in HNSCC and could be an independent prognostic biomarker.

Key words: CENPN, head and neck squamous cell carcinoma, prognosis

CHEN Helin, SHU Jiayu, DONG Qiang. Study on Prognostic Value of CENPN in Head and Neck Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2023, 39(8): 690-695.

References

[1] McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies [J]. Curr Treat Options Oncol, 2019, 20(5): 43.
[2] Simard EP, Torre LA, Jemal A. International trends in head and neck cancer incidence rates: diferences by country, sex and anatomic site [J]. Oral Oncol, 2014, 50(5): 387-403.
[3] Kitamura N, Sento S, Yoshizawa Y, et al. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma [J]. Int J Mol Ssi, 2020, 22(1): 240.
[4] Hoischen C, Yavas S, Wohland T, et al. CENP-C/H/I/K/M/T/W/N/L and hMis12 but not CENP-S/X participate in complex formation in the nucleoplasm of living human interphase cells outside centromeres [J]. PLoS One, 2018, 13 (3): e0192572.
[5] Talbert P, Henikoff S. Centromere drive: chromatin conflict in meiosis [J]. Curr Opin Genet Dev, 2022, 77: 102005.
[6] Zheng Y, You H, Duan JZ, et al. Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway [J]. Genes Genomics, 2022, 44(9): 1039-1049.
[7] Andres SA, Bickett KE, Alatoum MA, et al. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients [J]. Breast Cancer Res Treat, 2015, 152 (3): 545-556.
[8] Wu HL, Zhou Y, Wu HY, et al. CENPN acts as a novel biomarker that correlates with the malignant phenotypes of glioma cells [J]. Front Genet, 2021, 12: 732376.
[9] Wang QQ, Yu XY, Zheng ZW, et al. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma [J]. PeerJ, 2021, 9: e11342.
[10] Rahman MR, Islam T, Gov E, et al. Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis [J]. Medicina, 2019, 55 (1): 20.
[11] Oka N, Kasamatsu A, Endo-Sakamoto Y, et al. Centromere protein N participates in cellular proliferation of human oral cancer by cell-cycle enhancement [J]. J Cancer, 2019, 10(16): 3728 -3734.
[12] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods [J]. Int J Cancer, 2019, 144(8): 1941-1953.
[13] Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma [J]. Nat Rev Dis Primers, 2020, 6(1): 92-92.
[14] Zhou K, Gebala M, Woods D, et al. CENP-N promotes the compaction of centromeric chromatin [J]. Nat Struct Mol Biol, 2022, 29(4): 403-413.
[15] Qi CL, Huang ML, Zou Y, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis [J]. J Exp Clin Cancer Res, 2021, 40(1): 390.
[16] Zhang HY, Zhang W, Sun LL, et al. HJURP inhibits proliferation of ovarian cancer cells by regulating CENP-A/CENP-N [J]. Bull Cancer, 2022, 109(10): 1007-1016.
[17] Navarro AP, Cheeseman LM. Dynamic cell cycle-dependent phosphorylation modulates CENP-L-CENP-N centromere recruitment [J]. Mol Biol Cell, 2022, 33(10): ar87.
[18] Jonathan IE, Mahul BA, Samson WF, et al. The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer [J]. Arch Pathol Lab Med, 2021, 145(4): 461-493.
[19] Lawrence JO, Rebecca A, Michael V, et al. Effect of age and gender in non-smokers with oral squamous cell carcinoma: Multi-institutional study [J]. Oral Oncol, 2021, 116: 105210.
[20] Anne KHA, Elisabeth B, Hans JA. Personality, choice of coping and T stage predict level of distress in head and neck cancer patients during follow-up [J]. Eur Arch Otorhinolaryngol, 2012, 269(9): 2121-2128.
[21] Guigay J, Auperin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial [J]. Lancet Oncol, 2021, 22(4): 463-475.
[22] Okada M, Kato K, Cho BC, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3) [J]. Clin Cancer Res, 2022, 28(15): 3277-3286.